Adynovate Approval History
Adynovate (antihemophilic factor (recombinant) pegylated) is a human antihemophilic factor indicated for the control and prevention of bleeding episodes in patients with hemophilia A.
Development History and FDA Approval Process for Adynovate
|Dec 27, 2016||Shire Announces FDA Approval of Adynovate [Antihemophilic Factor (Recombinant), PEGylated] for Use in Children and Surgical Settings|
|Nov 13, 2015||FDA Approves Adynovate Modified Antihemophilic Factor for Hemophilia A|
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.